Priya Sharma
Analyst

Priya Sharma

Equity & ETF Correspondent

Priya covers US and international equities, ETFs, and index funds. Her analysis focuses on long-term portfolio construction and dividend investing strategies.

Priya Sharma's Articles (955)
Cerebras DCF Model Values Stock at $96, Well Below Current Price
Stocks
Cerebras DCF Model Values Stock at $96, Well Below Current Price
Salesforce Rises on BofA Upgrade, AI Analytics Acquisition
Stocks
Salesforce Rises on BofA Upgrade, AI Analytics Acquisition
DRAM ETF Faces Retreat Risk as Outflows Persist Despite Memory Sector Strength
ETFs
DRAM ETF Faces Retreat Risk as Outflows Persist Despite Memory Sector Strength
Tesco Hits 516p After Strong H1: Can the Rally Extend?
Stocks
Tesco Hits 516p After Strong H1: Can the Rally Extend?
SanDisk Slips 8% in Three Sessions as AI Storage Rally Faces Earnings Test
Stocks
SanDisk Slips 8% in Three Sessions as AI Storage Rally Faces Earnings Test
Micron's $3,000 Bull Case vs. the $1,100 Ceiling: Why MU Can't Break Out
Stocks
Micron's $3,000 Bull Case vs. the $1,100 Ceiling: Why MU Can't Break Out
Nio Shares Extend Slide in Hong Kong as Delivery Growth Slows
Stocks
Nio Shares Extend Slide in Hong Kong as Delivery Growth Slows
Nvidia Slips 5% From Record High as Portfolio Bets Falter, Reflection AI Deal Weighed
Stocks
Nvidia Slips 5% From Record High as Portfolio Bets Falter, Reflection AI Deal Weighed
Snowflake Shares Gain 6% After AI Marketplace Feature Debuts in Public Preview
Stocks
Snowflake Shares Gain 6% After AI Marketplace Feature Debuts in Public Preview
Tesla Stock Gains on AI Chip Plans, China Sales, and Analyst Optimism
Stocks
Tesla Stock Gains on AI Chip Plans, China Sales, and Analyst Optimism
T-Mobile Shares Slide to 14-Month Low as SpaceX Threat Looms; Valuation Debate Intensifies
Stocks
T-Mobile Shares Slide to 14-Month Low as SpaceX Threat Looms; Valuation Debate Intensifies
Moderna Surges 9% to 52-Week High on Nasdaq-100 Return, Cancer Data Ahead
Stocks
Moderna Surges 9% to 52-Week High on Nasdaq-100 Return, Cancer Data Ahead